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Dynamics of total, linear nonintegrated, and integrated HIV-1
DNA in vivo and in vitro
Abstract
BACKGROUND: In patients infected with human immunodeficiency virus type 1 (HIV-1), HIV-1
DNA persists during highly active antiretroviral treatment, reflecting long-lived cellular reservoirs of
HIV-1. Recent studies report an association between HIV-1 DNA levels, disease progression, and
treatment outcome. However, HIV-1 DNA exists as distinct molecular forms that are not distinguished
by conventional assays. METHODS: We analyzed HIV-1 RNA levels in plasma, CD4 cell counts, and
levels of integrated and nonintegrated HIV-1 DNA in peripheral blood mononuclear cells (PBMCs)
from patients with early or chronic infection before and during antiretroviral treatment. We also studied
HIV-1 DNA decay in primary CD4 T cells infected in vitro. HIV-1 DNA was analyzed using an assay
that is unaffected by the location of HIV-1 integration sites. RESULTS: HIV-1 RNA levels and total
HIV-1 DNA levels decayed rapidly in patients during receipt of suppressive antiretroviral therapy.
Ratios of total HIV-1 DNA levels to integrated HIV-1 DNA levels were high before initiation of therapy
but diminished during therapy. Levels of linear nonintegrated HIV-1 DNA decayed rapidly in vitro (t
(1/2) = 1- 4.8 days). CONCLUSION: Total HIV-1 DNA decays rapidly with suppression of virus
replication in vivo. Clearance of HIV-1 DNA during the first 6 months of therapy reflects a
disproportionate loss of nonintegrated HIV-1 DNA genomes, suggesting that levels of total HIV-1 DNA
in PBMCs after prolonged virus suppression largely represent integrated HIV-1 genomes.
Dynamics of Total, Linear Nonintegrated, and
Integrated HIV-1 DNA In Vivo and In Vitro
Kersten K. Koelsch,1,a Lin Liu,1 Richard Haubrich,1 Susanne May,1 Diane Havlir,3 Huldrych F. Günthard,8
Caroline C. Ignacio,1 Paula Campos-Soto,1 Susan J. Little,1 Robert Shafer,4 Gregory K. Robbins,6 Richard T. D’Aquila,7
Yuji Kawano,1 Karen Young,5 Phillip Dao,1 Celsa A. Spina,1,2 Douglas D. Richman,1,2 and Joseph K. Wong1,2,3
1University of California, San Diego, 2Veterans Affairs Medical Center, La Jolla, 3University of California, San Francisco, 4Stanford University,
Stanford, and 5Roche Molecular Diagnostics, Alameda, California; 6Harvard Medical School, Boston, Massachusetts; 7Vanderbilt University,
Nashville, Tennessee; 8Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, Switzerland
Background. In patients infected with human immunodeficiency virus type 1 (HIV-1), HIV-1 DNA persists
during highly active antiretroviral treatment, reflecting long-lived cellular reservoirs of HIV-1. Recent studies report
an association betweenHIV-1 DNA levels, disease progression, and treatment outcome. However, HIV-1 DNA exists
as distinct molecular forms that are not distinguished by conventional assays.
Methods. We analyzed HIV-1 RNA levels in plasma, CD4 cell counts, and levels of integrated and nonintegrated
HIV-1DNA in peripheral bloodmononuclear cells (PBMCs) from patients with early or chronic infection before and
during antiretroviral treatment. We also studied HIV-1 DNA decay in primary CD4 T cells infected in vitro. HIV-1
DNA was analyzed using an assay that is unaffected by the location of HIV-1 integration sites.
Results. HIV-1 RNA levels and total HIV-1 DNA levels decayed rapidly in patients during receipt of suppressive
antiretroviral therapy. Ratios of total HIV-1DNA levels to integratedHIV-1DNA levels were high before initiation of
therapy but diminished during therapy. Levels of linear nonintegratedHIV-1DNAdecayed rapidly in vitro (t1/ 2  1–
4.8 days).
Conclusion. Total HIV-1 DNA decays rapidly with suppression of virus replication in vivo. Clearance of HIV-1
DNA during the first 6 months of therapy reflects a disproportionate loss of nonintegrated HIV-1 DNA genomes,
suggesting that levels of total HIV-1 DNA in PBMCs after prolonged virus suppression largely represent integrated
HIV-1 genomes.
In HIV-1–infected patients, highly active antiretroviral
treatment (HAART) can lead to a substantial decrease in
virus replication and to undetectable levels of HIV-1
RNA in plasma [1, 2], but HIV-1 DNA remains detect-
able in cells from most HIV-1–infected patients during
sustained suppressive HAART. Recent studies report a
potential link between HIV-1 DNA levels and disease
progression, treatment success, and degree of virologic
suppression duringHAART [3–7]. HIV-1DNA exists in
a linear nonintegrated form, a circular nonintegrated
form, and as an integrated provirus. Integrated HIV-1
provirus is a fundamental constituent of the latent res-
ervoir, the major barrier to viral eradication [8–11].
This latent reservoir has a very long half-life; Siliciano et
al. [12] observed a half-life of44 months among indi-
viduals followed for up to 7 years. Studies investigating
the kinetics of the latent reservoir demonstrated a bipha-
sic decay of latently infected CD4 T cells after virus sup-
pression, suggesting that the decay dynamics during the
early phase of infection may reflect the kinetics of linear
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nonintegrated HIV-1 DNA [13]; however, HIV-1 DNA was not
directly measured in this study.
Circular and integrated forms of HIV-1 DNA are thought to
be stable [12, 14–16], whereas linear nonintegrated forms are
thought to be labile [17–19]. However, few studies have directly
addressed the decay of integrated and nonintegrated HIV-1
DNA in different clinical settings.
Furthermore, the biological significance of linear noninte-
grated HIV-1 DNA is unclear. One study demonstrated limited
transcription of nef by nonintegratedHIV-1DNA in quiescent T
cells [20], and another study showed transient expression of
early and late messages by nonintegrated HIV-1 DNA [17]. In
vitro decay analysis in the latter study suggested a rapid rate of
decay of linear nonintegratedDNA inmetabolically active trans-
formed and primary CD4 T cells.
Most recent studies investigating the dynamics of the latent
reservoir and kinetics of HIV-1 DNA have used terminal dilu-
tion coculture assays and direct measurement of HIV-1 DNA,
respectively [21, 22]. Neither method distinguishes between the
different molecular forms of HIV-1 DNA or their relative con-
tributions to latency. Some assays that do distinguish between
various forms of HIV-1 DNA rely on sequence-specific primers
that recognize repetitive host-genome motifs [23, 24] and may
be confounded by variation in the proximity of integration sites
to repetitive motifs [23, 25].
The aim of the present study was to determine the decay char-
acteristics of total, nonintegrated, and integratedHIV-1 DNA in
vivo and in vitro, using an assay that is not affected by the sites of
HIV-1 integration.
SUBJECTS, MATERIALS, AND METHODS
Patients with early infection were from the San Diego primary
infection cohort [26]; these patients initiated antiretroviral ther-
apy within 6 months after seroconversion and were selected on
the basis of available samples and successful suppression of vire-
mia during treatment. Patients with chronic infection were ran-
domly selected from among the University of California–San
Diego subpopulation of AIDS Clinical Trials Group 384 who
experienced successful suppression of plasma viremia during
their initial treatment regimen [27]. HIV-1 RNA was measured
frequently (every 1–4 months), and HIV-1 DNA was measured
on or around months 0, 6, and 12. Written informed consent
was obtained from all study patients in accordance with local
investigational review board guidelines.
Total DNA was extracted from patients’ peripheral blood
mononuclear cells (PBMCs) and in vitro–infected CD4 cells,
using the Qiagen DNA extraction kit (Qiagen) according to the
manufacturer’s protocol. Replicates of 500 ng of total DNAwere
loaded onto a 0.5% SeaKem Agarose gel (Cambrex); fraction-
ation of DNA was achieved with electrophoresis for 3 h at 60 V.
The 20-kb high molecular weight (HMW) band was excised
from the gel with a Gene-Capsule cutter (Geno Technology) to
achieve uniform gel-slice sizes. DNA was extracted from the gel,
using the Qiaex II gel extraction kit (Qiagen) in accordance with
the manufacturers’ protocol, with the following revisions: the
incubation time in QS buffer was extended to 20 min after add-
ing silica; following incubation, the silica was washed 3 times in
buffer QXI and 3 times in buffer phosphatidylethanolamine.
This procedure eliminated 97% to 99% of linear 9-kb HIV-1
DNA and99% of 2-LTR episomal DNA from the HMW frac-
tion in validation studies (data not shown).
Total DNAwas quantified using a real-time polymerase chain
reaction (PCR) assay. -actin–specific primers and probe were
provided with the ABI TaqMan -actin detection reagents
(ABI). Real-time PCR was performed in 25-L solutions con-
taining 5 L of DNA target, 12.5 L of TaqMan Universal Mas-
ter Mix (ABI), and 7.5 L of primers and probe (400 nmol/L
forward and reverse primers, with a 200 nmol/L probe) under
the following conditions: 50°C for 2 min and 95°C for 10 min,
followed by 95°C for 15 s and 60°C for 1 min (45 cycles). A
standard curve ranging from 30 to 0.1 ng of genomic DNA was
generated using reference human DNA (TaqMan Control Ge-
nomic DNA). Sample DNA content was calculated using the
sample cycle threshold signal values correlated to the standard
curve cycle threshold values.
HIV-1 DNA levels was ascertained for both total DNA and
HMW DNA, using a prototype HIV-1 DNA quantitative PCR
assay (Roche Molecular Diagnostics). HIV-1 DNA levels were
adjusted to the amount of input DNA and expressed as copies
per microgram of DNA. Levels of HIV-1 DNA in total DNA and
levels of integratedHIV-1DNA inHMWDNAwere determined
directly. Levels of nonintegrated HIV-1 DNAwere calculated by
subtracting the levels of integrated HIV-1 DNA in HMW DNA
from the levels of HIV-1 DNA in total DNA (nonintegrated
HIV-1 DNA level HIV-1 level in total DNA-integrated
HIV-1 DNA level). The overall coefficient of variation for the
Roche DNA assay is 30% for 86% of patient samples [28].
The coefficient of variation was 3% for HMWDNA determina-
tions and 9% for total DNA determinations in separate valida-
tion studies (data not shown).
For the in vitro studies, enriched preparations of CD4 lym-
phocytes were isolated from peripheral blood specimens from 2
healthy, HIV-1-seronegative donors. Briefly, a lymphocyte frac-
tion was obtained by Ficoll-Hypaque density gradient centrifu-
gation. CD4 lymphocytes were purified by negative selection
with magnetic cell sorting, using the CD4 T Cell Isolation Kit
(Miltenyi Biotec). Trypan blue dye exclusion revealed that the
resulting cell preparations were 95% viable; they contained
94%–98%CD4 lymphocytes, as monitored by automated flow
cytometry involving fluorescein isothiocyanate–conjugated
monoclonal antibodies to CD4.
Infectious virus stocks of the NL4-3 clone of HIV-1 were pre-
pared by transfecting plasmidDNA into theCEMT lymphoblas-
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toid cell line with Lipofectin (Invitrogen). For infection, virus
stocks were diluted in RPMI 1640 medium to achieve a multi-
plicity of infection of 0.5 (based on results of the p24 antigen
assay; Abbott). Immediately after CD4 cell isolation, aliquots of
3  106–5  106 quiescent lymphocytes in 1.0 mL were incu-
bated with virus for 16–18 h at 37°C.
Cells were cultured at 37°C in RPMI 1640medium containing
indinavir (0.1 mol/L) to inhibit viral replication and supple-
mented with L-glutamine (1 mmol/L), penicillin (50 U/mL),
streptomycin (50 g/mL), and 5% human AB serum (vol/vol).
Cells used for HIV-1 DNA analysis were sorted for viability, us-
ing flow cytometry involving propidium iodide staining.
Linear regression models were used to model log10 trans-
formed RNA decay over time for each patient (log10
RNAij  0i 1i weekij, i  1, . . ., 12; j  1, . . ., ti, where ti is
the number of visits for patient i). Exponential regression mod-
els were used to model DNA decay over time for each patient
(DNAij  0i exp [1i weekij]; graphs are presented on the log10
scale). For the RNA analyses, time points were included from 4
weeks after treatment initiation to the time of first RNA suppres-
sion (50 copies per mL of plasma). For DNA analyses, time
points were included from treatment initiation through 12
months of follow-up. A Wilcoxon rank-sum test was used to
compare average slopes between patients with early and those
with chronic infection. Wilcoxon rank-sum tests were also used
to compare differences between patients with early and those
with chronic infection with respect to total, integrated, and lin-
ear nonintegrated DNA levels before HAART initiation and to-
tal, integrated, and nonintegrated DNA levels during HAART.
Wilcoxon signed-rank tests were used for within-patient com-
parisons, namely for comparing total, integrated, and noninte-
grated DNA levels before and after HAART initiation (overall
and separately for patients with early infection and patients with
chronic infection). Spearman rank correlation coefficients are
presented to describe the associations between integrated and
nonintegrated DNA separately for all patients, those with early
infection, and those with chronic infection. P values of.05 are
considered statistically significant. P values of.05 but.10 are
considered borderline significant. No adjustments were made
for multiple comparisons. For RNA values below the detection
limit (50 copies per mL of plasma), the detection limit was
used.
RESULTS
Study population. Table 1 shows plasma HIV-1 RNA levels
and CD4 cell counts before HAART initiation (i.e., at baseline)
and during HAART (i.e., during virus suppression). All patients
reached complete and sustained virus suppression (defined as
50 HIV-1 RNA copies per mL of plasma) during HAART. The
median HIV-1 plasma RNA level was higher among patients
with early infection, but the difference was not statistically sig-
nificantly different from that among patients with chronic infec-
tion (P  .2). The median CD4 T cell count before initiation of
Table 1. HIV-1 RNA loads, CD4 cell counts, and highly active antiretroviral therapy (HAART) for patients
with early or chronic HIV-1 infection.
Patient, by group
HIV-1 RNA level
before HAART, log10
copies/mL plasma
CD4 cell count, cells/L blood
HAARTBefore HAART During HAART
Early infection
E1 5.76 497 577 ZDV,3TC, NFV
E2 6.71 496 839 ABC,3TC,ZDV,APVr
E3 6.18 532 500 ABC,3TC, ZDV
E4 5.45 311 325 ZDV,3TC,APVr
E5 6.30 308 842 d4T,3TC,ABC,APVr
Overall, median value 6.18 496 577 . . .
Chronic infection
C1 6.06 27 137 ZDV,3TC, EFV
C2 4.71 166 349 ZDV,3TC, EFV
C3 5.68 153 425 ddI,d4T, EFV, NFV
C4 6.63 7 557 ddI,d4T, EFV, NFV
C5 6.10 64 535 ddI,d4T, EFV
C6 5.30 271 415 ZDV,3TC, NFV
C7 5.20 19 272 ZDV,3TC, NFV
Overall, median value 5.68 64 415 . . .
All patients, median value 5.94 218 462 . . .
NOTE. All patients had an HIV-1 RNA level of50 copies per mL plasma during treatment. Values obtained during HAART were
recorded 12 months after HAART initiation. ABC, abacavir; APVr, amprenavir-ritonavir; ddI, didanosine; d4T, stavudine; EFV,
efavirenz; NFV, nelfinavir; ZDV, zidovudine; 3TC, lamivudine.
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HAART was significantly lower among patients with chronic
infection (P  .003).
HIV-1 RNA levels. Decay of HIV-1 RNA levels in patients
with early infection and patients with chronic infection were
ascertained for a follow-up period of 12 months (figure 1A and
1B). All patients achieved undetectable HIV-1 RNA levels after
initiation of HAART and were selected for further HIV-1 DNA
decay analysis. HIV-1 RNA decay is shown in figure 1A for all
patients; figure 1B shows observed data and linear fits of log10
RNA decay for individual patients. One patient (E4) had an
HIV-1RNA level of50 copies permLof plasma at the first time
point after HAART initiation, and the data could not be
modeled.
HIV-1 DNA levels. Levels of linear nonintegrated HIV-1
DNA per g of PBMC DNA (i.e., total DNA level-integrated
DNA level) and levels of integratedHIV-1DNAperg of PBMC
DNA were determined for each patient individually before ini-
tiation of HAART and for up to 12 months of follow-up (figure
2). Note that, in figure 2C, the fit of the model appears to be
suboptimal for some patients at later observations. This is be-
cause the assumed exponential decay model requires monoto-
nicity and focuses on the initial decrease. There were no signifi-
cant differences in the total DNA level (P  .43), the integrated
DNA level (P  .76), and the nonintegrated DNA level
(P  .27) at baseline between patients with early infection and
patients with chronic infection. However, before HAART initi-
ation, the median total HIV-1 DNA level (431 copies per g of
PBMCDNA)was significantly higher than the integratedHIV-1
DNA level (58 copies per g of PBMC DNA) for all patients
(P  .01).
Figure 1. Plasma HIV-1 RNA decay for patients with early infection (E1–E5) and patients with chronic infection (C1–C7), overall (A) and for individual
patients (B). Plots were truncated for each patient when the HIV-1 RNA level decreased to 50 copies/mL plasma; patient E4 was excluded from this
analysis, because the patient had HIV-1 RNA levels of 50 copies/mL plasma after week 4.
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For all patients, the total HIV-1 DNA level was markedly re-
duced after 12months ofHAART (P  .01) (figure 3). The non-
integrated HIV-1 DNA level in particular diminished dramati-
cally during this period. When considered separately, patients
with early infection and patients with chronic infection had sub-
stantial reductions in the total HIV-1 DNA level (median reduc-
tions, 371 copies perg of total DNA [P  .062] and 351 copies
per g of total DNA [P  .047], respectively) and the noninte-
grated HIV-1 DNA level (median reductions, 314 copies per g
of total DNA [P  .062] and 187 copies per g total DNA
[P  .078], respectively) after initiation of HAART, although
not all reductions were statistically significant (figure 2). The
Figure 2. Levels of total HIV-1 DNA (A) and nonintegrated HIV-1 DNA (B) overall and levels of total HIV-1 DNA for individual patients with early
(E1–E5) or chronic (C1–C7) HIV-1 infection (C), before and after 12 months of highly active antiretroviral therapy.
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lack of statistical significance likely reflects the small sample sizes
for each group of patients.
The median rates of decay of total HIV-1 DNA (1.03 vs.
0.25; P  .048) and nonintegrated HIV-1 DNA (0.79 vs.
0.32; P  .073) were faster for patients with early infection
than for patients with chronic infection. The median rates of
decay of integrated HIV-1 DNA were not significantly different
between groups.
To determine the relationship between the levels and decay
rates of total HIV-1 DNA, nonintegrated HIV-1 DNA, and inte-
grated HIV-1 DNA, we compared levels at baseline and levels
after HAART initiation. Overall, although the total HIV-1 DNA
level and the integrated HIV-1 DNA level were significantly dif-
ferent before HAART initiation (P  .01), they were not signif-
icantly different after HAART initiation (P  .68) (figure 3). As
with baseline comparisons, there was no significant difference in
the total HIV-1 DNA, integrated HIV-1 DNA, and noninte-
grated HIV-1 DNA levels after HAART initiation between pa-
tients with early infection and patients with chronic infection
(P 	 .10 for all comparisons).
Half-life of nonintegrated HIV-1 DNA in vitro. Assessment
of the molecular half-life of nonintegrated HIV-1 DNA was deter-
mined in vitro. The levels of HIV-1 DNA in total DNA and inte-
grated HIV-1 DNA in HMW DNA were determined over the
course of 14 days after inoculationof viable, restingCD4Tcells.No
integratedHIV-1DNAwas detectable at any time point after infec-
tion. HIV-1 DNA levels peaked 5 days after infection and decayed
rapidly over the remaining 9 days of the experiment. In duplicate
experiments, the calculated half-life of decay was consistent (mean
t1/2, 2.9 days) (figure 4).
DISCUSSION
Apool of latently infected and resting, long-livedmemory cells is
established in the earliest stages of HIV-1 infection [8–10, 13,
29], a major obstacle to the eradication of this virus. To better
understand the nature of this obstacle and the role that these
stable cellular reservoirs of infection play in viral pathogenesis,
detection and characterization of the different forms of HIV-1
DNA in infected cells have been performed in patients with early
[10, 30] and patients with chronic [31, 32] HIV-1 infection.
Measurement of HIV-1 DNA levels during successful therapy in
different clinical settings, including when treatment was started
early or late during disease [30, 33, 34], during treatment inten-
sification [35], or during treatment interruption [7, 15, 36, 37],
has provided additional insights on the relationship between cel-
lular reservoirs ofHIV-1 and replication ofHIV-1. The pretreat-
ment HIV-1 DNA level in PBMCsmay also be a relevant marker
in predicting residual viremia for patients receiving an identical
HAART regimen [3], and HIV-1 DNA levels and HIV-1 DNA
decay rates correlate with levels of residual replication and virus
transcription during HAART [34, 37].
Interpretation of HIV-1 DNA data from in vivo studies is
complicated, because although different forms of HIV-1 DNA
are present, most of these studies have only measured the total
HIV-1 DNA level. Because the biological characteristics and im-
pact of the various molecular forms of HIV-1 DNA differ, a
more precise analysis of HIV-1 DNA levels in various clinical
settings should involve distinguishing between these forms. It
Figure 4. Rate of decay of total HIV-1 DNA in primary CD4 cells
infected in vitro. Representative results from duplicate experiments in-
volving cells from separate donors are shown.
Figure 3. Levels of total, nonintegrated, and integrated HIV-1 DNA for
all patients before and after receipt of highly active antiretroviral treat-
ment therapy for 12 months. P values above the figure represent com-
parisons of across DNA fractions at a single time point, whereas those
below the figure represent comparisons of single fractions across time
points.
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was the aim of this study to determine the decay dynamics for
total, nonintegrated, and integrated HIV-1 DNA in vivo during
successful HAART, using assay reagents that have been well val-
idated for HIV-1 in clinical samples. Characteristics of the se-
lected study population permitted some comparison of the de-
cay characteristics for patients with early infection and those
with chronic infection. We found that, in both patient groups,
nonintegrated HIV-1 DNA appeared to be cleared rapidly upon
initiation of HAART.
Furthermore, we showed here for the first time that, during
successful therapy (defined as suppression of the plasma HIV-1
RNA level to 50 copies per mL of plasma), the median total
and integrated HIV-1 DNA levels did not differ significantly,
which presumably reflects the preferential clearance of noninte-
grated HIV-1 DNA. These findings are important in regard to
the interpretation of HIV-1 DNA data as a marker in HIV-1
disease and therapy evaluation.
Several assays have been used to characterize integrated
HIV-1 DNA, linear nonintegrated HIV-1 DNA, and circular
forms of HIV-1 DNA in vitro and in vivo [15, 16, 24, 38, 39].
One key problemwith PCR assays that use primers targeting repet-
itive genomic sequence motifs is the potential variability in assay
efficiency, which is attributable to the nonrandom distribution of
repetitivemotifs and the variation in numbers and location of inte-
gration sites [23, 25].These assaysmight lead tounderestimationor
overestimation of the integrated HIV-1 DNA level, depending on
the nature of the reference standard used. Our approach, adapted
from that of others [40, 41], involved aDNA size-separation proce-
dure, which allows for the quantitation of integrated HIV-1 DNA
levels without regard for HIV-1 integration sites. DNA gel-
separation procedures can lead to cross contamination of frag-
mentedHMWDNA in the lowmolecular weight (LMW) fraction,
with cross-contamination rates of 10%–50%. Therefore, direct
quantitation of nonintegrated LMWDNA bymeans of this proce-
dure is not reliable.
However, cross-contamination rates from LMW DNA into
the HMW fraction (including episomal forms) are significantly
lower (typically,1% of LMW DNA is seen in the HMW frac-
tion [K. Koelsch, Y. Kawano, P. Li, and J. Wong, unpublished
data]), which makes it possible to accurately determine the
amount of HIV-1DNA in both total DNA andHMWDNA. The
separate quantitation of total HIV-1 DNA levels and integrated
HIV-1 DNA levels also allowed us to quantify linear noninte-
grated HIV-1 DNA levels by subtraction, with excellent repro-
ducibility (coefficients of variation, 0.091 for total DNA and
0.032 for integrated DNA). Our results show that levels of non-
integrated HIV-1 DNA are high during active virus replication
but that these forms decay promptly during suppression of virus
replication after initiation of HAART.
Clearance of nonintegrated HIV-1 DNAwas faster in patients
with early infection than in patients with chronic infection, al-
though the difference was not statistically significant. Because
the pretherapy RNA levels in patients with early infection are
higher than those in patients with chronic infection, it is possible
that higher numbers of cells are targeted by replicating virus
before therapy initiation and that amore substantial initial clear-
ance of these cells occurs after initiation of HAART. It was not
the aim of the study to directly compareDNAdecay rates among
patients receiving different antiviral regimens; therefore, no ef-
fort was made to compare these varying decay rates in detail.
Remarks about the limitations of this study are warranted.
First, recent data suggest that CD4 cells serving as latent reser-
voirs of HIV-1may consist of phenotypically heterogeneous cel-
lular populations that harbor HIV-1 with discrete genotypes,
which, in turn, exhibit discrete clearance kinetics [21, 42]. The
present study does not distinguish HIV-1 DNA clearance rates
for these separate reservoirs. Such studies would be valuable
once reliable markers for these different cell types have been
identified. Second, we did not specifically assay for circular epi-
somal forms, because earlier work by others [15, 38] has shown
that such forms represent a minority of total HIV-1 DNA and
because our validation assays indicate that the gel separation
procedure largely excludes episomal circles from the HMW
band. However, because direct measurements of linear uninte-
grated forms were not performed on patient samples, the linear
unintegrated HIV-1 DNA levels we computed are in fact a com-
posite of both linear and episomal unintegrated forms.
Before initiation of therapy, episomal forms would be ex-
pected to be a small minority of the total unintegrated HIV-1
DNA [38]; however, duringHAART, theymight become amore
sizable constituent. Nevertheless, because total HIV-1 DNA and
integrated DNA levels were not significantly different during
treatment, this distinction between episomal and linear uninte-
grated forms should be relatively less important for patients re-
ceiving therapy. Finally, it should be noted that the number of
patients studied herewas small and highly selected for thosewith
a well-documented response to therapy. It is possible that some
patients receiving combination antiretrovirals with good but in-
complete suppression of viral replication might retain higher
levels of detectable linear nonintegrated forms [10] or circular
episomes [15, 16, 43]. Furthermore, even among these highly
selected patients, we cannot exclude the possibility that residual
unintegrated DNA persists at low levels or continues to be gen-
erated. Indeed, in individual patients, total HIV-1 DNA levels
were slightly higher than integrated HIV-1 DNA levels even
when assayed 6 months after the start of suppressive therapy.
Our in vitro data indicating a short molecular half-life for unin-
tegrated HIV-1 DNA species would support the conclusion that
even these low levels of residual unintegrated DNA are the result
of ongoing HIV-1 replication [22, 35, 44].
Other studies have reported a correlation between baseline
HIV-1 DNA levels and virus rebound after structured treatment
interruption, with residual levels of plasma viremia [3, 7, 36],
and in response to “standard” HAART [4, 33]. It is not possible
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to resolve whether these observations of pretreatment HIV-1
DNA that are a composite of integrated provirus and labile non-
integrated forms reveal effects attributable to the size of the sta-
ble cellular reservoir or, alternatively, reveal the host and viral
factors that correlate with efficiency of viral entry and reverse
transcription. An approach such as that taken here may permit
such studies to be revisited with the aim of distinguishing these
effects.
Measuring HIV-1 DNA levels during successful HAARTmay
be an important tool in determining the success of new and
future approaches to virus eradication and of long-term therapy
regimens that use structured treatment interruption as a way of
reducing therapy-related adverse effects and costs. Our study
confirms that nonintegrated HIV-1 DNA is short-lived in vitro
[40] and extends this observation to the in vivo setting. Nonin-
tegratedHIV-1DNAdecays rapidly during virus suppression, so
that, after 6months to 1 year of suppressive therapy, total HIV-1
DNA levels approximate integrated HIV-1 DNA concentra-
tions. As a consequence, separate measurements of the different
forms of HIV-1 DNA during HAART may not be necessary for
patients that successfully suppress plasma viremia. New and
standardized quantitation protocols for measuring HIV-1 DNA
in these patients seem feasible and desirable for longitudinal
analysis of HIV-1 treatment strategies.
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